Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

Cancer

Volumn 118, Issue 7, 2012, Pages 1946-1954

  Kim, Jenny J ^a   Vaziri, Susan A J ^a   Rini, Brian I ^a   Elson, Paul ^a   Garcia, Jorge A ^a   Wirka, Robert ^a   Dreicer, Robert ^a   Ganapathi, Mahrukh K ^a   Ganapathi, Ram ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Renal carcinoma; SNPs; Sunitinib; VEGF; VEGFR2

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; GENOMIC DNA; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CANCER PATIENT; CLEAR CELL CARCINOMA; CONFIDENCE INTERVAL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TOXICITY; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863338437     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26491     Document Type: Article

References (29)

1. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-8, 2006.
2. Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9:1793-805.
3. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol. 2009; 297:R1-R5.
4. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-477.
5. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010;36:416-424.
6. Vaziri SA, Kim J, Ganapathi MK, Ganapathi R. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep. 2010;12:102-108.
7. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res. 2009;15:5297-5302.
8. Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8:2496-2508.
9. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672-4678.
10. Facemire CS, Nixon AB, Griffiths R, et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652-658.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
12. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008;180:860-865; discussion 865-8666.
13. Rini BI, Schiller JH, Fruehauf JP, et al. Association of diastolic blood pressure (dBP) ≥90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol. 2008;26:abstr 3543.
14. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989. (Pubitemid 32289743)
15. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 2005;76:449-462. (Pubitemid 40250525)
16. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
17. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543-550. (Pubitemid 47106142)
18. Huez I, Creancier L, Audigier S, Gensac M-C, Prats A-C, Prats, H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. 1998;18:6178-6190. (Pubitemid 28500509)
19. Zhai R, Liu G, Wei Zhou LS, et al. Vascular endothelial growth factor genotypes, haplotyes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008;14:612-617.
20. Kawai Y, Sakano S, Korenaga Y, et al. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol. 2007;52:1147-1155. (Pubitemid 47332024)
21. Bruyère F, Hovens CM, Marson MN, et al. VEGF Polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol. 2010;184:1273-1278.
22. Steffensen KD, Waldstrøm M, Brandslund I, et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010;117:109-116.
23. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-nduced toxicity. J Clin Oncol. 2009;27:4406-4412.
24. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443-448. (Pubitemid 32037619)
25. Houk BE, Bello CL, Poland B, et al: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 66:357-371, 2010.
26. Lindauer A, Di Gion P, Kanefendt F, et al. Pharmacokinetic/- pharmacodynamic modeling of biomarker response to suntinib in healthy volunteers. Clin Pharmacol Ther. 2009;87:601-608.
27. Feldman DR, Baum, MS, Ginsberg, MS, et al. Phase I trial of bevacizumab plus escalated doses of suntinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27: 1432-1439.
28. Rini BI, Garcia JG, Cooney MM, et al. Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol. 2010;28:e284-e285.
29. Feldman DR, Scappaticci FA, Motzer RJ. Reply to B.I. Rini et al. J Clin Oncol. 2010;28:e286-e2287.